Liozon Eric, Loustaud Véronique, Fauchais Anne-Laure, Soria Pascale, Ly Kim, Ouattara Baly, Rhaiem Kaïef, Nadalon Sylvie, Vidal Elisabeth
Department of Internal Medicine, University Hospital, Limoges, France.
J Rheumatol. 2006 Aug;33(8):1606-14.
To determine the frequency of occurrence of malignancy concurrently with temporal arteritis (TA), as well as features and outcome of the vasculitis in such cases.
In a series of 271 consecutive patients with TA (219 biopsy-proven), we retrospectively analyzed the frequency and type of malignancy concurrent with vasculitis (less than 1 year before or after), as well as the main features and outcome of TA in this setting. We also surveyed all cases published in the French-British literature.
We observed 20 patients with TA and concurrent malignancy and reviewed 27 similar published reports. GCA was documented pathologically in 86% of the cases. The time between diagnosis of TA and that of malignancy averaged 3.5 months (synchronous diagnoses in 27 patients). Various locations of cancers were found, particularly the gastrointestinal tract (9 cases); blood malignancies accounted for 45% of cases (lymphoid disorder in 9, myelodysplastic syndrome in 11, chronic myelogenous leukemia in 1). In our patients, logistic regression analysis failed to demonstrate differences between those with and without malignancy, except for a higher frequency of rheumatic involvement in the former group (60% vs 30%; p = 0.01). The initial response to steroid treatment was good in 92% of 40 assessable patients, and the vasculitis course mirrored that of malignancy in only 2 patients. Regarding the outcome of TA, no differences were observed in our patients with and without malignancy.
Concurrent malignancy in TA is not a rare finding, being observed in up to 7.4% of the cases. Solid malignancies and hematological disorders, especially myelodysplastic syndromes, may represent precipitating factors for development of TA, which infrequently run a paraneoplastic course. Patients with and without malignancy seem almost indistinguishable regarding features and outcome of TA. Physicians who care for patients with TA should be mindful of this potential association, even in typical cases.
确定颞动脉炎(TA)并发恶性肿瘤的发生率,以及此类病例中血管炎的特征和转归。
在连续的271例TA患者(219例经活检证实)中,我们回顾性分析了与血管炎并发的恶性肿瘤的发生率和类型(在血管炎发生前或后不到1年),以及在此情况下TA的主要特征和转归。我们还查阅了法国 - 英国文献中发表的所有病例。
我们观察到20例TA并发恶性肿瘤的患者,并回顾了27篇类似的已发表报告。86%的病例经病理证实为巨细胞动脉炎。TA诊断与恶性肿瘤诊断之间的时间平均为3.5个月(27例为同步诊断)。发现癌症的部位各不相同,尤其是胃肠道(9例);血液系统恶性肿瘤占病例的45%(9例为淋巴系统疾病,11例为骨髓增生异常综合征,1例为慢性粒细胞白血病)。在我们的患者中,逻辑回归分析未能显示有和无恶性肿瘤患者之间的差异,只是前一组风湿性受累的频率较高(60%对30%;p = 0.01)。40例可评估患者中92%对类固醇治疗的初始反应良好,只有2例患者的血管炎病程与恶性肿瘤病程相似。关于TA的转归,有和无恶性肿瘤的患者之间未观察到差异。
TA并发恶性肿瘤并非罕见,在高达7.4%的病例中可观察到。实体恶性肿瘤和血液系统疾病,尤其是骨髓增生异常综合征,可能是TA发生的诱发因素,TA很少呈副肿瘤病程。有和无恶性肿瘤的患者在TA的特征和转归方面似乎几乎没有区别。即使在典型病例中,诊治TA患者的医生也应留意这种潜在关联。